Head-To-Head Review: Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) and TriSalus Life Sciences (NASDAQ:TLSI)

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) and TriSalus Life Sciences (NASDAQ:TLSI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Profitability

This table compares Fresenius SE & Co. KGaA and TriSalus Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius SE & Co. KGaA	0.71%	4.88%	2.02%
TriSalus Life Sciences	N/A	N/A	-166.18%

Insider and Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Fresenius SE & Co. KGaA has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Fresenius SE & Co. KGaA and TriSalus Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius SE & Co. KGaA	0	2	2	0	2.50
TriSalus Life Sciences	0	0	0	0	N/A

Earnings and Valuation

This table compares Fresenius SE & Co. KGaA and TriSalus Life Sciences’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius SE & Co. KGaA	$24.01 billion	0.70	-$639.61 million	$0.11	68.37
TriSalus Life Sciences	$18.51 million	13.69	-$59.04 million	N/A	N/A

TriSalus Life Sciences has lower revenue, but higher earnings than Fresenius SE & Co. KGaA.

Summary

Fresenius SE & Co. KGaA beats TriSalus Life Sciences on 6 of the 10 factors compared between the two stocks.

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.